CDA | Evidence Driven
CDA | Evidence Driven

Cabometyx for Renal Cell Carcinoma Resubmission – Details

Details

Files
Generic Name:
Cabozantinib
Project Status:
Complete
Therapeutic Area:
Renal Cell Carcinoma (RCC)
Manufacturer:
Ipsen Biopharmaceuticals Canada Inc.
Brand Name:
Cabometyx
Project Line:
Reimbursement Review
Project Number:
PC0163-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Strength:
20 mg, 40 mg & 60 mg
Tumour Type:
Genitourinary
Indications:
Renal Cell Carcinoma
Funding Request:
For the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior therapy.
Sponsor:
Ipsen Biopharmaceuticals Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Cabozantinib (Cabometyx) RCC Resubmission – pERC Final Recommendation Final Recommendation February 20, 2019 View PDF
Cabozantinib (Cabometyx) RCC Resubmission - Final Clinical Guidance Report Guidance Reports February 20, 2019 View PDF
Cabozantinib (Cabometyx) RCC Resubmission - Final Economic Guidance Report February 20, 2019 View PDF
Cabozantinib (Cabometyx) RCC Resubmission - pERC Initial Recommendation Initial Recommendation January 31, 2019 View PDF
Cabozantinib (Cabometyx) RCC Resubmission – PAG Feedback on Initial Recommendation Feedback February 20, 2019 View PDF
Cabozantinib (Cabometyx) RCC Resubmission – Submitter Feedback on Initial Recommendation Feedback February 20, 2019 View PDF
Cabozantinib (Cabometyx) RCC Resubmission – Clinician Feedback on Initial Recommendation Feedback February 20, 2019 View PDF
Cabozantinib (Cabometyx) RCC Resubmission – Patient COI Declarations COI Declarations February 20, 2019 View PDF
Cabozantinib (Cabometyx) RCC Resubmission – Clinician COI Declarations COI Declarations February 20, 2019 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : March 7, 2019